Preparing for Direct Acting Antivirals (DAAs) in PracticeNew Paradigms in the Management of HCV Sherilyn C. Brinkley, MSN, CRNP Nurse Practitioner/Program.
SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1.
1 This activity has been supported by an independent medical education grant from Bristol Myers Squibb. 2013 IC-HEP Educational supporters include Bristol.
Sanaa Kamal, M.D., Ph.D. Professor Ain Shams University, Cairo, Egypt Clinical Challenges in the Management of Hepatitis C Genotype 4.
HCV research: Recent findings and future challenges
1 Sponsored for Continuing Medical Education Credit by Rush University Medical Center Supported by an independent educational grant from Vertex Pharmaceuticals.
Best of HCV From AASLD 2013
Structural polymorphism within entire HCV NS5A region
